Discover how a newly developed platform technology from The University of North Carolina at Chapel Hill can enhance RNAi ...

Nutcracker Therapeutics is driving down costs, accelerating speed of processing and improving scalability with an end-to-end, GMP-grade production process. Healthcare is on the cusp of a ...

Elegen and Nutcracker Therapeutics launched a pilot program to demonstrate what they label the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--City Therapeutics, Inc. announced its launch today with a vision to lead the future of RNA interference (RNAi)-based medicine. City Therapeutics™ aims to harness ...

Researchers at the University of North Carolina at Chapel Hill have unveiled a platform technology designed to strengthen the potency of RNA interference therapies, a field that has promised targeted ...